Nano-X Imaging (NNOX) Stock News

Nanox (NNOX) has received EU MDR CE mark certification for HealthOST, an AI-powered software for spine assessment that analyzes routine CT scans to detect vertebral height loss and bone mineral density. The software, which already has FDA 510(k) clearance from April 2022, helps identify musculoskeletal diseases like osteoporosis before fractures occur. HealthOST integrates with existing PACS systems and requires no additional imaging or radiation. The technology proved effective in the ADOPT study across four UK NHS trusts, identifying over 3,450 new patients with vertebral compression fractures from 37,220 CT scans - up to six times more than the national average. This advancement is particularly significant for Europe, where over 25.5 million women have osteoporosis, and annual fracture-related costs exceed €56 billion, with cases expected to increase 25% by 2034.

Nanox (NASDAQ: NNOX), a medical imaging technology company, announced its participation in the upcoming Sidoti Small Cap Conference, scheduled for June 11-12, 2025. The company's management will deliver a presentation on Wednesday, June 11 at 1:45 PM ET. The virtual conference presentation will be accessible via live webcast, with interested parties able to access it through a dedicated link or the company's website under Events & Presentations. Institutional investors have the opportunity to schedule one-on-one virtual meetings with Nanox management through Sidoti & Company.

Nanox (NASDAQ: NNOX) reported its Q1 2025 financial results, showing revenue of $2.8 million, up from $2.6 million in Q1 2024. The company posted a net loss of $13.2 million, increased from $12.2 million year-over-year. Key developments include FDA 510(k) clearance for the Nanox.ARC X multi-source digital tomosynthesis system and multiple commercial agreements for marketing Nanox.ARC and Nanox.AI solutions. The company has over 60 units in various implementation stages and expects to grow to over 100 units by end of 2025. Teleradiology services generated $2.6 million in revenue with a 17% GAAP gross profit margin. The company maintains a strong financial position with $72.9 million in cash and equivalents as of March 31, 2025.

Nanox (NASDAQ: NNOX), a medical imaging technology company, has scheduled its first quarter 2025 financial results announcement for May 22, 2025, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring CEO and Acting Chairman Erez Meltzer and CFO Ran Daniel, who will discuss the quarterly results and provide a business update.

Nanox (NASDAQ: NNOX) has received FDA 510(k) clearance for its new Nanox.ARC X multi-source digital tomosynthesis system. The clearance, obtained in under 30 days, allows for general use tomographic imaging, including musculoskeletal, pulmonary, intra-abdominal, and paranasal indications in adult patients.

The system features Nanox's proprietary digital Nanox.SOURCE and advanced tomosynthesis technology with cold cathode, enabling enhanced 3D body visualization. Key improvements include:

• Streamlined single-unit design with reduced footprint
• 'Plug and play' one-day installation
• Standard power operation (110v/230v 16A)
• Cables-free design for improved safety and maintenance

The company plans to offer the Nanox.ARC X alongside the current Nanox.ARC later this year, expanding its product portfolio.

Nanox (NASDAQ: NNOX) reported Q4 2024 financial results and business updates. The company generated $3.0 million in revenue, up from $2.4 million in Q4 2023. Key achievements include FDA clearance for Nanox.ARC general use and CE mark approval in the EU.

Financial highlights: Net loss increased to $14.1 million compared to $10.2 million in Q4 2023. The company reported a gross loss of $2.9 million. Cash position stood at $83.5 million as of December 31, 2024.

Business developments include new partnerships with Ezra AI Inc. for cancer detection screening and expansion into EU markets through distributors in Romania and Greece. The company raised approximately $37.8 million through the sale of 5.0 million ordinary shares in Q4 2024.

Nanox (NASDAQ: NNOX) announced that its subsidiary Nanox AI will present new data from the ADOPT study at four major medical conferences across Europe from March to June 2025. The study, completed in February 2025, evaluated HealthVCF at four NHS trusts in the UK.

Key findings show that HealthVCF analyzed 37,220 routine medical CT scans and identified over 3,450 new asymptomatic patients with vertebral compression fractures - up to six times more than the national NHS average. The AI-enabled Fracture Liaison Services demonstrated up to 10% reduction in patient refracture rates and cost savings of up to £50,000 per healthcare organization.

The company's newer FDA-cleared solution, HealthOST, offers improved fracture measurement precision and can detect low bone mineral density in routine CT scans without additional imaging or radiation exposure.

Nanox (NASDAQ: NNOX), a medical imaging technology company, has scheduled its fourth quarter and fiscal year 2024 financial results announcement for March 31, 2025, before market open. The company will host a conference call at 8:30 a.m. ET featuring CEO and Acting Chairman Erez Meltzer and CFO Ran Daniel to discuss the results and provide a business update.

Nanox (NASDAQ: NNOX) will present new clinical data for its Nanox.ARC digital tomosynthesis system at ECR 2025 in Vienna. The system recently received both CE mark certification for European marketing and FDA 510(k) clearance in December 2024.

Three key studies will be presented:

• A 19-patient clinical study showing diagnostic value in 17 cases for fracture detection
• A phantom study demonstrating superior lung nodule detection in simulated obesity conditions compared to standard X-ray
• A case series highlighting improved musculoskeletal imaging applications

The Nanox.ARC system features a proprietary digital X-ray source with cold cathode technology, providing 3D body views while reducing radiation exposure and reading time. Clinical results showed enhanced detection of occult fractures, improved cast imaging, and potential reduction in CT scan requirements.